| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:34 | Sanofi vollzieht Übernahme von Dynavax - Aktie wird von der NASDAQ genommen | 2 | Investing.com Deutsch | ||
| 15:30 | Personalis Gets Medicare Coverage For Lung Cancer Surveillance Test | 1 | Benzinga.com | ||
| 15:23 | NSE - DYNAVAX TECHNOLOGIES CORP - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 2 | SEC Filings | ||
| 15:18 | BioCardia, Inc.: BioCardia Files Pre-Submission for FDA Approval of Helix Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart | 1 | GlobeNewswire (USA) | ||
| 15:15 | BioCardia, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15:10 | DYNAVAX TECHNOLOGIES CORP - 8-K, Current Report | 1 | SEC Filings | ||
| 15:10 | Sanofi: Sanofi completes the acquisition of Dynavax | 160 | GlobeNewswire (Europe) | Sanofi completes the acquisition of Dynavax
Paris, February 10, 2026. Sanofi today announced that it has completed theacquisition of Dynavax Technologies Corporation (Dynavax). The acquisition... ► Artikel lesen | |
| 15:07 | Celularity receives $12.2 million from sale of tax credits | 1 | Investing.com | ||
| 15:06 | Codexis, Inc.: Codexis Achieves ISO 9001:2015 Certification | 2 | GlobeNewswire (USA) | ||
| 15:06 | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline | 2 | GlobeNewswire (USA) | ||
| 15:06 | Creative Medical receives WHO designation for second cell therapy | 3 | Investing.com | ||
| 15:00 | CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| 14:59 | Hoth Therapeutics Says GDNF Beats Semaglutide In Preclinical Obesity, Liver Disease Study New Data | - | RTTNews | ||
| 14:54 | FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment | 1 | Benzinga.com | ||
| 14:46 | Genprex erhält Patent in Australien für Krebstherapie | 1 | Investing.com Deutsch | ||
| 14:42 | SenesTech to manage Amazon sales of Evolve rodent products directly | 6 | Investing.com | ||
| 14:42 | Genprex receives patent approval in Australia for cancer therapy | 1 | Investing.com | ||
| 14:36 | Oncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified Pipeline | 1 | GlobeNewswire (USA) | ||
| 14:36 | Celularity Inc.: Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses | 33 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2... ► Artikel lesen | |
| 14:36 | RenovoRx, Inc.: RenovoRx Establishes RenovoCath Medical Advisory Board | 1 | GlobeNewswire (USA) |
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | Aktuelle Nachrichten | |||
|---|---|---|---|---|---|---|---|
| REGENXBIO | 8 | - | -9,25 % | Regenerative Medizin auf dem Vormarsch: Exosomen, Gen- und Zelltherapien als Wegbereiter neuer Heilansätze | |||
| EVOTEC | 7 | 44 | -1,35 % | SDAX: Evotec-Aktie schießt zweistellig nach oben | Eine Kaufempfehlung von Berenberg entfacht neuen Optimismus bei Evotec und katapultiert die Biotech-Aktie an die Indexspitze. Die Aktie der Evotec hat am Dienstagmittag ein Kursfeuerwerk gezündet und... ► Artikel lesen | ||
| BIOGEN | 6 | 54 | -1,51 % | Ihre wichtigsten Termine: Frische Zahlen von Philip Morris, Under Armour, Toyota, Biogen, Societe Generale | © Foto: Hiro Komae/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:30... ► Artikel lesen | ||
| BIONTECH | 5 | 13 | 0,00 % | BioNTech- und Nvidia-Aktien verkauft, Medline und Alphabet rein: Erste 13F-Filings sind da! | Der britische Vermögensverwalter Baillie Gifford hat als einer der ersten sein 13F-Filing für das 4. Quartal abgegeben. Unter den großen Namen im Portfolio gibt es ein paar spannende Veränderungen.... ► Artikel lesen | ||
| CSL | 5 | 7 | -4,42 % | Warum dieses Biotech-Unternehmen Rekordumsätze erzielt: 60% Umsatzsteigerung im Dezemberquartal | |||
| DYNAVAX | 5 | 4 | -0,23 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 10.02.2026 | Das Instrument 5FM NO0013637181 KMC PROPERTIES ASA NK 2 EQUITY wird cum Kapitalmassnahme gehandelt am 10.02.2026 und ex Kapitalmassnahme am 11.02.2026 The instrument 5FM NO0013637181 KMC PROPERTIES... ► Artikel lesen | ||
| INNOVENT BIOLOGICS | 5 | 4 | +1,09 % | Innovent And Lilly Expand Collaboration To Advance Global Oncology & Immunology Drugs | INDIANAPOLIS (dpa-AFX) - Innovent Biologics Inc. (IVBXF, 1801.HK) announced a new strategic collaboration with Eli Lilly and Company. This marks the seventh partnership between the two companies... ► Artikel lesen | ||
| FARON PHARMACEUTICALS | 5 | - | 0,00 % | Faron Pharmaceuticals Ltd: Notice To The Extraordinary General Meeting | TURKU, FI / ACCESS Newswire / February 9, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Shareholders of Faron Pharmaceuticals Ltd (business ID: 2068285-4, the "Company") are notified of the Extraordinary... ► Artikel lesen | ||
| PATRYS | 4 | 1 | - | PATRYS LIMITED: Change of Director's Interest Notice - BL | |||
| CYBIN | 4 | - | +3,77 % | Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution | Former President of Shire PLC's ("Shire") Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior... ► Artikel lesen |